Key Highlights
- MBRX shares are trading down 2.99% at $7.64, versus a prior close of $7.87.
- Third-quarter net loss narrowed to $6.5 million from $25.4 million.
- Loss was $9.59 per share, narrower than the $13.00 market estimate.
- Cash and equivalents were $7.3 million, down from $8.9 million at year-end.
Moleculin Biotech (NASDAQ:MBRX) shares are trading lower today after the company reported third-quarter results and said it has completed treatment of all 90 patients in Part A of its pivotal Phase 2/3 MIRACLE trial. The net loss was $6.5 million, or $9.59 per share, against a $13.00 per-share market estimate.
Houston-based Moleculin is developing Annamycin, also known as naxtarubicin, for relapsed or refractory acute myeloid leukemia, and the trial combines it with cytarabine. The company also studies the drug in pancreatic cancer models.
Prior-Year Warrant Charge Explains the Narrower Net Loss
The net loss compared with $25.4 million a year earlier, which included a non-cash loss of about $20.6 million tied to the issuance of warrant liabilities. For the first nine months, Research and Development expenses were about $15.3 million.
Cash and equivalents were about $7.3 million at September 30, versus $8.9 million at December 31, and net cash used in Operating Activities over the nine months was about $21.7 million.
MIRACLE Trial Progress and Cardiac Safety Data Frame the Next Catalyst
The company expects to report comprehensive Part A data in the first quarter of 2027 to support dose selection for Part B, which is planned for the first half of 2027. Interim MIRACLE results have been accepted for presentation at the 2026 American Society of Hematology annual meeting.
A peer-reviewed analysis of 90 patients across five trials, independently evaluated by a cardio-oncology laboratory, found no clinical or subclinical evidence of treatment-related cardiotoxicity, including at cumulative exposures above traditional lifetime limits for conventional anthracyclines. Separate preclinical data suggest the drug may help make immunologically cold pancreatic tumors more visible to the immune system.
Outlook: Part A Readout and Funding Needs Are the Next Tests
The company is approaching its most important milestone with a modest cash balance relative to recent spending. Investors will watch the first-quarter 2027 data, the ASH presentation and the Market research data management said it will release soon.






Please wait processing your request...